Innovative profile of the Russian pharmaceutical industry

InnoThe article examines the specifics of innovative activity of Russian drug manufacturers, which in the context of a COVID-19 pandemic become a matter of national security. The research is based on panel data: out of a total of 1,816 enterprises in the industry, a sample of 345 innovatively active enterprises is formed with a time series of data 20 years long. The sample is diversified by the scale of enterprise activity into 4 groups: micro enterprises, small, medium, and large enterprises. These types of enterprises are compared both in absolute terms — size of investments in intangible assets, age, and in relative ones — frequency of investments in innovations, coefficient of autonomy, profitability of sales and assets, share of intangible assets in revenue and assets. The analysis was supplemented by enterprises not included in the sample to identify the effectiveness of innovation in the industry. The result is the innovative profile of industrial enterprises in the context of the scale of their activities. The conclusion is drawn about the specifics of the domestic pharmaceutical industry innovation activity, which generally coincides with the established distribution of roles in the global pharmaceutical industry, when large enterprises are leaders in the innovations development and implementation. Russian large companies also tend to use micro enterprises to implement risky projects. The authors conclude that in Russia, the foundations have been formed for transition to a new model of pharmaceutical industry innovative development. This model is based on cooperation of small and large businesses.

1. McKinsey (2018). Innovations in Russia: A sustainable source of growth. McKinsey Innovation Practice. (In Russian).

2. Brizhanina T. A. (2014). Small business: Еssence, advantages, development. Chelyabinsk State University Bulletin, No. 2, pp. 32—37. (In Russian).

3. Varfolomeev D. (2019). Investments in the agro-industrial complex: Stages of development, trends, features. Ekonomika i Zhizn, May 30. (In Russian).

4. Vasilenok V. L., Safronova Z. S., Brazevich D. S. (2018). Small business as a factorof development of innovative economy. Scientific Journal NRU ITMO. Series: Economics and Environmental Management, No. 1, pp. 98—104. (In Russian).] https://doi.org/10.17586/2310-1172-2018-11-1-98-104

5. Gokhberg L. M., Ditkovskiy K. A., Kuznetsova I. A. et al. (2019). Indicators of innovation in the Russian Federation: 2019: Data book. Moscow: HSE. (In Russian).

6. Evseeva I. N., Buev V. V., Rachkovskaya I. A., Chepurenko A. Y. (1998). Interaction of small enterprises with large-scale production at the regional level. Moscow: ISARP. (In Russian).

7. Eliseev A. N. (2009). Trends in the development of small business in Russia. Tambov University Review. Series: Humanities, No. 9, pp. 56—61. (In Russian).

8. Zholobov P. S. (2017). Using the experience of development institutions of the BRICS countries in the activities of Vnesheconombank Group. Economics: Yesterday, Today and Tomorrow, Vol. 7, No. 1A, pp. 249—258. (In Russian).

9. Zabolotskaya V. V. (2012). Theoretical and conceptual approaches to the study of the essence of small business. Ekonomika: Teoriya i Praktika, No. 1, pp. 53—59. (In Russian).

10. Mamedyarov Z. A. (2018). Innovative development of the global pharmaceutical industry: Thesis. Moscow: IMEMO RAN. (In Russian).

11. Podshivalova M. (2014). Analysis of the quality of basic social and economic institutions that form environment of small business development. Voprosy Еkonomiki, No. 6, pp. 97—111. (In Russian). https://doi.org/10.32609/0042-8736-2014-6-97-111

12. Simonova E. V. (2010). Forms of integration of small, medium and large businesses: Development problems. Scientific Journal of Orel SIET, No. 2, pp. 335—340. (In Russian).

13. Syrtsova L. V. (2011). Experience of organizing and evaluating the effectiveness of small business in public catering. Transport Вusiness of Russia, No. 1, pp. 75—76. (In Russian).

14. Kheyfets B. (2013). Deoffshorization of economy: International experience and Russian specifics. Voprosy Ekonomiki, No. 7, pp. 29—48. (In Russian). https://doi.org/10.32609/0042-8736-2013-7-29-48

15. Schumpeter J. A. (2008). The theory of economic development. Capitalism, socialism and democracy. Moscow: Eksmo. (In Russian).

16. Adams R., Bessant J., Phelps R. (2006). Innovation management measurement: A review. International Journal of Management Review, Vol. 8, No. 1, pp. 21—47. https:// doi.org/10.1111/j.1468-2370.2006.00119.x

17. Adizes I. (1979). Organizational passages-diagnosing and treating lifecycle problems of organizations. Organizational Dynamics, Vol. 8, No. 1, pp. 3—25. https://doi.org/10.1016/0090-2616(79)90001-9

18. Anthony J. H., Ramesh K. (1992). Association between accounting performance measures and stock prices: A test of the life-cycle hypothesis. Journal of Accounting and Economics, Vol. 15, No. 2—3, pp. 203—227. https://doi.org/10.1016/0165-4101(92)90018-W

19. Ardito L., Petruzzelli A., Savino T. (2018). Maturity of knowledge inputs and innovation value: The moderating effect of firm age and size. Journal of Business Research, No. 86, pp. 190—201. https://doi.org/10.1016/j.jbusres.2018.02.009

20. Dickinson V. (2011). Cash flow patterns as a proxy for firm life-cycle. Accounting Review, Vol. 86, No. 6, pp. 1969—1994. https://doi.org/10.2308/accr-10130

21. Dierickx I., Cool K. (1989). Asset stock accumulation and sustainability of competitive advantage. Management Science, Vol. 35, No. 12, pp. 1504—1511. https://doi.org/10.1287/mnsc.35.12.1504

22. Ding M., Eliashberg J., Stremersch S. (2014). Innovation and marketing in the pharmaceutical industry. Emerging Practices, Research, and Policies. New York: Springer. https://doi.org/10.1007/978-1-4614-7801-0

23. Ettlie J. E., Rubenstein A. H. (1987). Firm size and product innovation. Journal of Product Innovation Management, Vol. 4, No. 2, pp. 89—108. https://doi.org/10.1016/0737-6782(87)90055-5

24. Evaluate Pharma (2020). World preview 2020, outlook to 2026.

25. Fishburn C. S. (2015). Translational medicine: The changing role of big pharma. In: M. Wehling (ed.). Principles of translational science in medicine: From bench to bedside, 2nd ed. Elsevier, pp. 313—325. https://doi.org/10.1016/b978-0-12-800687-0.00032-3

26. Forsman H. (2011). Innovation capacity and innovation development in small enterprises. A comparison between the manufacturing and service sectors. Research Policy, Vol. 40, No. 5, pp. 730—750. https://doi.org/10.1016/j.respol.2011.02.003

27. Hilmersson F. P., Hilmersson M. (2020). Networking to accelerate the pace of SME innovations. Journal of Innovation & Knowledge, Vol. 6, No. 1, pp. 43—49. https:// doi.org/10.1016/j.jik.2020.10.001

28. Huergo E., Jaumandreu J. (2004). Firms’ age, process innovation and productivity growth. International Journal of Industrial Organization, Vol. 22, No. 4, pp. 541—559. https://doi.org/10.1016/j.ijindorg.2003.12.002

29. Kiriri P. N. (2004). Small and medium enterprises (SMEs): Validating life cycle stage determinants. Australian Journal of Business and Social Inquiry, Vol. 2, No. 1.

30. Kurji N. (2019). The future of pharma: The role of biotech companies. Forbes, May 29. https://www.forbes.com/sites/forbestechcouncil/2019/05/29/the-future-ofpharma-the-role-of-biotech-companies/?sh=6e505fc76bb3

31. Lopes C. M., Scavarda A., Hofmeister L. F., Thomé A. M. T., Vaccaro G. L. R. (2016). An analysis of the interplay between organizational sustainability, knowledge management, and open innovation. Journal of Cleaner Production, Vol. 142, pp. 476—488. https://doi.org/10.1016/j.jclepro.2016.10.083

32. Mark A. (2018). The role of big pharma. The Hawk Newspaper. Special Issue: Opioid, April 18. http://www.sjuhawknews.com/the-role-of-big-pharma

33. Mazzarol T., Reboud S., Volery T. (2010). The influence of size, age and growth on innovation management in small firms. International Journal of Sustainable Agricultural Management and Informatics, Vol. 52, No. 1/2, pp. 98—117. https://doi.org/10.1504/IJTM.2010.035857

34. Miller D., Friesen P. H. (1984). A longitudinal study of the corporate life cycle. Management Science, Vol. 30, No. 10, pp. 1161—1183. https://doi.org/10.1287/mnsc.30.10.1161

35. Morck R., Yeung B. (2001). The economic determinants of innovation. Industry Canada Occasional Paper, No. 25.

36. Muda S., Rahman M. R. C. A. (2016). Human сapital in SMEs life cycle perspective. Procedia Economics and Finance, Vol. 35, pp. 683—689. https://doi.org/10.1016/S2212-5671(16)00084-8

37. Murphey R. (2020). A framework for comparing R&D productivity at big pharma companies vs. biotech startups. Journal of Commercial Biotechnology, Vol. 25, Vol. 4. https://doi.org/10.5912/jcb951

38. National Science Board (2012). Science and engineering indicators 2012. Arlington, VA: National Science Foundation.

39. Nieminen J. (2019). Innovation maturity matrix — A model to successful innovation transformation. Viima.com, November 1. https://www.viima.com/blog/innovation-maturity-matrix

40. OECD, Eurostat (2018). Oslo manual 2018: Guidelines for collecting, reporting and using data on innovation. Luxembourg: OECD Publishing.

41. Robinson R. (2020). Small pharma driving big pharma innovation. PharmaVOICE, January. https://www.pharmavoice.com/article/2020-01-pharma-innovation

42. Szetto E. (2001). Innovation сapacity: Working toward a mechanism for improving innovation within an inter-organizational network. The TQM Magazine, Vol. 12, No. 2, pp. 149—152. https://doi.org/10.1108/09544780010318415

43. Yoo J., Lee S., Park S. (2019). The effect of firm life cycle on the relationship between R&D expenditures and future performance, earnings uncertainty, and sustainable growth. Sustainability, Vol. 11, No. 8, article 2371. https://doi.org/10.3390/su11082371